You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(06160.HK)第三季度收入達9100萬美元 環比增39%同比增81.6%
格隆匯 11-06 08:21

格隆匯11月6日丨百濟神州(06160.HK)公佈,2020年第三季度,實現產品總收入達9100萬美元(約合6億元),季度環比增長39%,與去年同期相比增長81.6%。

上述時期內收入完全來自產品淨收入,而季度同比有所增加主要歸因於百澤安®在華和百悦澤®在華及在美的產品收入,但其中部分與新基物流公司(隸屬百時美施貴寶)授權在中國銷售產品的產品收入下滑相抵消。

2020年公司第三季度研發費用約3.5億美元(約合23億元),前三季度累計研發投入超過9.4億美元(約合62億元),為國內藥企研發投入首位。

研發費用的增加主要歸因於用於正在進行以及新啟動的後期關鍵性臨牀試驗持續增長的費用,與授權候選藥物預付款相關的研發費用,與安進公司合作相關的開發成本,新增的藥物註冊登記準備,以及與商業化前活動和供應相關的生產成本。

2020年前三季度實現產品總收入2.1億美元(約合13.9億元),其中抗PD-1抗體百澤安®前三季度實現銷售收入近1億美元(約合6.6億元)。

另外,公司首席財務官兼首席戰略官樑恆博士(Howard Liang)計劃在完成工作交接以及公司任命新首席財務官後從百濟神州退休。預計將於2021年第一季度末正式生效。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account